DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This office action is in response to the amendment received on August 3rd, 2026.
Any objections or rejections not reiterated below are hereby withdrawn.
Claim 1 is pending and was examined on the merits.
Withdrawal of Objections and Rejections
Applicant’s arguments, filed August 3rd, 2026, with respect to the objection to the specification have been fully considered and are persuasive. The applicant has amended the specification to correct the spelling of the term “Pygeum”. The objection to the specification has been withdrawn.
Applicant’s arguments, filed August 3rd, 2026, with respect to the rejection of claim 1 under have been fully considered and are persuasive. On August 3rd, 2026, the applicant filed a terminal disclaimer for the instant application with respect to application # 18665934. This terminal disclaimer has been approved. The rejection of claim 1 under has been withdrawn.
Pending Objections and Rejections
Claim 1 is objected to because of the following informalities: the applicant has corrected the spelling of the term "Pygeum". Appropriate correction is suggested.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claim 1 is rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more.
Applicant's arguments filed August 3rd, 2026 have been fully considered but they are not persuasive. The compounds in the claimed compositions are in a composition having a physical form distinct from any of the naturally occurring sources. The applicant alleges “The compound physical properties compared to the raw natural are different, …”. However, the claims are drawn to a nutritional complex. Therefore, rather than analyzing the claimed product based on physical properties, the examiner analyzes the claimed product based on biological functions or activities; see MPEP 2106.04(c) II. B. “Appropriate characteristics can be expressed as the nature-based product’s structure, function, and/or other properties, and are evaluated on a case-by-case basis”. In their remarks, the applicant implies that the combination (understood as the claimed combination of ingredients) shows an unexpected result in comparison with a separate use, and that the “product of the present invention has been chemically treated to obtain the final combination, whereby the complex shows an unexpected synergistic effect”. However, the applicant has not cited support in the instant disclosure for a synergistic effect, and the examiner has not found support for a synergistic effect in the instant disclosure. The rejection of claim 1 under 35 U.S.C 101 is maintained.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over Phillips (NZ 600777 A); and further in view of Li and Zhang (CN 107596049 A), abbreviated "Li"; Weston (US 20130101569 A1), Morley (US 10709659 B1); Uehara (JP 2002322050 A); Ishikawa et al. (JP 2012144440 A), abbreviated "Ishikawa"; Shmid (RU 2336890 C2); IVY GmbH (DE 202018101130 U1); and Hasebe (JP 2004189688 A).
Applicant's arguments filed August 3rd, 2026 have been fully considered but they are not persuasive. The applicant recites the combination of ingredients of the nutritional complex and implies that this combination shows . The examiner thanks the applicant for clearly and concisely presenting their position. However, it is noted that the feature upon which applicant relies (i.e., an unexpected synergistic effect in comparison with the effect of each compound by itself according to its properties) is not recited in the rejected claim, the applicant has not pointed out where this feature is supported in the instant disclosure, and the examiner has not found support for this feature in the instant disclosure. The rejection of claim 1 under 35 U.S.C. 103 is maintained.
Conclusion
No claims are allowed.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert F Spaine whose telephone number is (571)272-9099. The examiner can normally be reached 8:00 AM - 4:00 PM United States Eastern Time, Monday-Friday.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571) 272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/R.F.S./Examiner, Art Unit 1655
/ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655